KRAS and lung adenocarcinoma: Among these, KRAS mutations are the most common oncogenic aberrations found in almost 25%–30% of lung adenocarcinoma cases, and were the first genetic lesions identified in lung adenocarcinoma more than 30 years ago (5, 6).